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Abstract
The role of variable regions of HIV-1 gp120 in immune escape of HIV has been investigated. However, there is scant
information on how conserved gp120 regions contribute to virus escaping. Here we have studied how molecular sequence
characteristics of conserved C3, C4 and V3 regions of clade C HIV-1 gp120 that are involved in HIV entry and are target of
the immune response, are modulated during the disease course. We found an increase of ‘‘shifting’’ putative N-glycosylation
sites (PNGSs) in the a2 helix (in C3) and in C4 and an increase of sites under positive selection pressure in the a2 helix during
the chronic stage of disease. These sites are close to CD4 and to co-receptor binding sites. We also found a negative
correlation between electric charges of C3 and V4 during the late stage of disease counteracted by a positive correlation of
electric charges of a2 helix and V5 during the same stage. These data allow us to hypothesize possible mechanisms of virus
escape involving constant and variable regions of gp120. In particular, new mutations, including new PNGSs occurring near
the CD4 and CCR5 binding sites could potentially affect receptor binding affinity and shield the virus from the immune
response.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) gp120 envelope
protein is characterized by a remarkable genetic variability [1–3],
due to extensive replication of the virus and to a high mutation
rate of the reverse transcriptase [4]. This variability is largely
responsible for the ability of the virus to escape the host immune
response, in particular neutralizing activity of antibodies [5–8].
The role of the variable regions of gp120 (V1 to V5) in promoting
virus escape has been reported by several groups, including ours
[9–15]. These studies have shown that both amino acid sequence
length and number of putative N-glycosylation sites (PNGSs) in the
V1, V2 and V4 variable regions of the protein change during the
course of the disease, generating HIV variants resistant to
neutralizing antibodies. Similar mechanisms of escape have been
observed in different HIV-1 subtypes of the M group [10,15–18],
although subtype-specific differences may be present [9,19].
In HIV-1 subtype C, the most widespread HIV clade worldwide
and the prevalent one in Southern Africa [20,21], we and others
have shown that during the chronic stage of the disease the V1 and
V4 variable regions of gp120 undergo a significant increase of
their aminoacid sequence length and new PNGSs are generated
[9,20], while the V5 undergoes changes in its net electrical charge
during the course of the disease. These changes may play a role in
glycan packing and immune evasion [9,14,22].
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Few studies have been conducted to date that have investigated
the modulation of molecular sequence characteristics of the
constant regions of gp120 during the course of the disease, even
though these regions are responsible for HIV entry into the cell,
and are important targets of the immune response, including
neutralizing antibodies. The V3 domain, known to be variable in
clade B and D viruses, is relatively conserved in HIV-1 subtypes A,
C, G, E and H [Los Alamos website. Available:http://www.
hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/1999/7/
V3LoopEvolution.pdf. Accessed 2014 March 31, and 9, 23, 24]. It
plays a critical role in virus entry, since it binds both CCR5 and
CXCR4 receptors and is a target of neutralizing antibodies
[9,23,25,26]. The C3-V4 region has been reported to be a major
target of the early autologous neutralizing response in HIV-1
subtype C infection and the N-terminal portion of C3, which
contains the a2 helix region, may play a role in virus escape
processes [6,24,27,28]. It has also been reported that some
residues in C3 bind the CD4 receptor, in association with amino
acids in the C4 region [29–32].
In the present study, we have therefore investigated how amino
acid characteristics of the constant C3, C4 and V3 regions of HIV-
1 subtype C (i.e. sequence length, number of PNGSs, number of
sites under positive selection pressure and electrical charges) are
modulated during the course of the disease. We used a novel
integrative bioinformatics sequence analysis which allowed us to
hypothesize a model to explain how conformational changes in
these regions may regulate virus escape from the immune
response.
Materials and Methods
Ethics Statement
The study was approved by the Committee for Research on
Human Subjects (Medical) at the University of Witwatersrand and
by the Ministry of Health and Social Welfare Scientific Ethical
Committee of Swaziland. All participants provided written
informed consent to participate in the study.
Sample collection, determination of disease stage and
description of the cohorts
A total of 72 plasma samples were collected from in the time
period 2005 to 2007 from HIV-positive individuals, living in South
Africa and Swaziland, all naı¨ve for antiretroviral therapy (ART);
24 samples were obtained from the 2006 Swaziland HIV National
Serosurvey [33,34], 24 samples from the Chris Hani Baragwanath
Hospital (CHBH) in Soweto, Johannesburg, South-Africa, in the
framework of the activities included in the AVIP project
(European Commission website. Available: http://ec.europa.eu/
research/health/infectious-diseases/poverty-diseases/projects/84_
en.htm. Accessed 2014 March 31) and 24 samples from the HIV/
AIDS National Referral Laboratory (NRL) at the Government
Hospital in Mbabane, Swaziland, in the framework of activities
linked to the Italian AIDS Programme. Ethical clearance for these
studies was obtained from local Ethical Committees.
The 72 patients were classified for disease stage into 3 groups,
based on Avidity Index (AI) assay data [34,35] and CD4+ T cell
number, as previously described [9]. Briefly, by AI assay we
identified those HIV infections that occurred within 6 months
from blood drawing, independently of their CD4+ T cell number.
A number of 24 patients were classified as recently infected (ES =
Early disease Stage). All these patients were from Swaziland,
collected in the frame of the 2006 Swaziland National Serosurvey
[33,34]. Patients that by AI were identified having an established
infection were further classified into patients at chronic or late
disease stage, according to their CD4+ T cell number. Specifically,
24 patients with a CD4+ T cell count .200/ml were classified in
the chronic disease stage group (CS = Chronic disease Stage),
whereas 24 patients with a CD4+ T cell count #200/ml were
included in the late disease stage group (LS = Late disease Stage).
CD4+ T cell number median values were 544,5/ml (values ranging
from 418 to 811) and 122/ml (values ranging from 7 to 199) for CS
and LS groups, respectively. The 24 patients included in the CS
group were from South Africa. Samples from 6 out of these 24
patients were collected in 2005. The remaining 18 samples were
collected in 2006. The 24 patients included in the LS group were
from Swaziland. Samples from 13 out of these 24 patients were
collected in 2006. The remaining 11 samples were collected in
2007.
CD4+ T cell count
CD4+ T cell count was performed by means of MultiTEST and
TruCOUNT tubes (Beckton Dickinson) according to the manu-
facturer’s instruction.
Viral RNA extraction and sequence amplification
Viral RNA was extracted from 0.5 ml of plasma using Qiamp
viral RNA mini Kit (Qiagen), after treatment with Heparinase
(Sigma).
The V1 to V5 coding region in the env gene was amplified by
RT-PCR using SuperScriptTM One-Step RT-PCR System
(Invitrogen) and specifically designed outer primers for clade C.
The following primers were used: AC-Env Outer For =
59CAGATGCATGAGGATATAATCA39; ED12 m Outer Rev
= 59AGTGCTTCCTTGCTGCTCCCAA39. The RT-PCR mix
was composed of 0.5 to 1 mg of RNA and an RT/Taq buffer
mixture containing dATP, dCTP, dTTP, dGTP 0.4 mM (Roche),
MgSO4 2.4 mM (Invitrogen), 1 ml RT/Taq-platinum (Invitrogen),
RNase inhibitor 40 U/ml (Invitrogen), and primers 10 mM (MWB-
Biotech); RT-PCR reaction was carried out using a thermal cycler
(Eppendorf) and the following program: 45uC for 309 for retro-
transcription and 94uC for 29 for the RT denaturation; the
resulting cDNA was amplified as follows: 94uC for 150, 50uC for
300 and 68uC for 19300for a total of 40 cycles and a final extension
step at 68uC for 79.
The resulting PCR product was again amplified in a nested
PCR, using specifically designed primers in order to obtain
nucleotide sequences corresponding to the V3-C3 and the V4-C4-
V5 Env regions, respectively. Primers specific for each region were
the following: for the V3-C3 region: V3C3ForA =
59CTGTTAAATGGTAGCCTAGC39 and V3C3RevA =
59GCAATAGAAAAATTCTCC39. If amplification failed, a
nested PCR was repeated using another couple of inner primers,
i.e. V3C3ForB = 59CACAGTACAATGTACACATG39 and
V3C3RevB = 59RCAATAGAAAAATTCTCCTC39; for the
V4-C4-V5 region: V4-AFor59 = 59GTRGAGGA-
GAATTTTTCTATTG39, V5-ARev59= TATAATT-
CACTTCTCCARTTGTC. If amplification failed, a nested
PCR was repeated using another couple of inner primers: V4-
BFor59 = TTTAATTGTRGAGGAGAATTTTTCTATTG39,
V5-BRev59 TATTTATATAATTCACTTCTCCAATTGTC39.
Each nested PCR reaction was conducted as follows: 1–5 ml
aliquot of the amplified product was added to a reaction mixture
containing dNTPS 200 mM (Roche), MgCl2 2.5 mM (Invitrogen),
the couple of 20 mM primers corresponding to the region that had
to be amplified (MWB-Biotech) and AmpliTaq Gold DNA
polymerase 2.5 U/ml (Applied Biosystems). Amplifications were
carried out specifically for each region, as following: V3–C3: 96uC
for 79 (1st cycle), then 150at 94uC, 300 at 50uC, 300 at 72uC, for 40
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cycles; V4–C4–V5 region: 96uC for 79 (1st cycle), then 150 at
94uC, 300 at 44uC, 300 at 72uC, for a total of 40 cycles and a final
extension step of 79 at 68uC.
DNA purification and sequencing
Amplified DNA of each region was purified using Qiaquick
PCR purification kit (Qiagen), according to the manufacturer’s
protocol. The DNA samples were then quantified and checked for
purity by measuring absorbance at 260 nm and 280 nm. The V3–
C3 and V4–C4–V5 amplified regions were then sequenced using
BigDye (Applied Biosystem), with the same primers as the nested
PCR. Sequencing was performed on uncloned PCR products to
identify the prevalent viral quasispecies.
The electropherogram analysis was edited using Chromas Pro
(Technelysium website. Available: www.technelysium.com.au/
ChromasPro.html. Accessed 2014 March 31). All sequences were
aligned using ClustalW by Bioedit [36] and corrected for the
multiple alignment by manual editing. The nucleotide sequences
were translated into amino acid sequences using GeneRunner
(www.generunner.net) and further codon-aligned using BioEdit
[36].
Phylogenetic analysis
Phylogenetic analysis was based on the V3-V5-coding region
from 72 HIV-1 variants isolated from the 72 patients (one variant/
patient) included in the cohorts. It was carried out using the PAUP
software (version 4.0) (http://paup.csit.fsu.edu/downl.html) with
the K81 model of substitution and using both Neighbor-Joining
(NJ) and Maximum Likelihood (ML) treebuilding methods. The
evolutionary model was chosen as the best fitting nucleotide
substitution model in accordance with the results of the
Hierarchical Likelihood Ratio Test (HLRT) implemented in the
MODELTEST software (version 3.6) [37].
The parameters for the nucleotide substitution model were
estimated by the ML method using a NJ tree (Jukes-Cantor
distance) as the base tree [38].
The statistical robustness and reliability of the branching order
within phylogenetic trees were confirmed by either a bootstrap
analysis using 1000 replicates, for the NJ tree, or the zero branch
length tests for the ML tree. All calculations were performed with
PAUP software (version 4.0).
Analysis of predicted co-receptor usage and
identification of PNGSs
The analysis of predicted co-receptor usage was performed by
using Geno2pheno (Genafor website. Available: http://
coreceptor.geno2pheno.org/index.php. Accessed 2014 March
31) upgraded version, June 17, 2011.
Identification of PNGSs was performed by using N-GLYCO-
SITE (Los Alamos website. Available: http://www.hiv.lanl.gov/
content/sequence/GLYCOSITE/glycosite.html. Accessed 2014
March 31).
Analysis of electric charges
To determine the electric charge of each region, the algebraic
sum of all charged residues, both positive and negative, was
considered as total electric charge (Qtot). The sum of all positive
charged residues was considered as total positive charge (Qpos) and
the sum of all negative charged residues as total negative charge
(Qneg).
An original Matlab (the MathWorks Inc. USA) program was
written to yield the distribution of Qtot, Qpos and Qneg directly
from the *.fas files with the aligned sequences. Charge distribu-
tions were analyzed with the Wilcoxon’s rank sum test, after a
preliminary checking of the non-Gaussian nature of the distribu-
tions using the Kolmogorov-Smirnov test, as previously described
[39]. Finally, the charge correlation coefficient was calculated with
Matlab.
Codon specific dN/dS ratio
The CODEML program implemented in the PAML 3.14
software package (UCL website. Available: http://abacus.gene.
ucl.ac.uk/software/paml.html. Accessed 2014 March 31) was used
to investigate the adaptive evolution of the V3, C3 and C4 regions
of HIV-1 env gene [40]. For each region, sequence alignment was
performed prior to testing which amino acids were under positive
selection. Six models of codon substitution, M0 (one-ratio), M1a
(nearly neutral), M2a (positive selection), M3 (discrete), M7 (beta),
and M8 (beta and omega) were applied in this analysis [41]. Since
these models are nested, we used codon-substitution models to fit
the model to the data using the likelihood ratio test (LRT) [42].
The ‘‘Bayes empirical Bayes’’ (BEB) approach implemented in
M2a and M8 was used to determine the positively selected sites by
calculating the posterior probabilities (P) of the different classes for
each site [43].
Finally, the Shannon’s entropy analysis was performed by using
the Entropy software (Los Alamos website. Available: http://www.
hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html.
Accessed 2014 March 31).
The strength of positive selection (i) for each amino acid site was
calculated as previously described [29], by defining the Weighted
Mean Value (vi) as:
vi~
X11
k~1
fkivki
where vki represents the k-th v value for the i-th site, and the
weight fki is the associated posterior probability, according to
model M8 (10 values of v are chosen for the discrete beta
distribution, and another value of v is not constrained by the beta
distribution and is allowed to be greater than 1). For each pair of
data set, each one associated to a disease stage, we tested whether
the strength of positive selection was significantly different (H1), as
opposed to being equivalent (H0), by using a paired Wilcoxon rank
sum test with a continuity correction applied to the normal
approximation for the P values [44]. Only shared sites having a
weighted mean vi value greater than 1 in the two data sets being
compared were included in the test.
Three-dimensional mapping and contact maps
The core structure used for mapping the positive selected
residues corresponds to the X-ray structure of CD4-bound JR-FL
gp120 (Protein Data Bank [PDB] ID: 2B4C) [45]. This structure
was chosen because it provides the spatial representation of V3,
and is therefore useful for the identification of the PS residues in
V3 (besides those in C3 and C4) in the appropriate structural
context. Moreover, the chosen structure derives from a strain that
has the same co-receptor usage as the majority of the isolates
hereby characterized. Three-dimensional images were generated
using the pyMOL v. 1.3 software (PyMOL website. Available:
http://www.pymol.org/ Accessed 2014 March 31).
For generation of the contact maps, we referred to the same
gp120 structure used for 3D mapping [45]. The contact map is a
distance matrix that identifies, in a known 3D structure (e.g., taken
from Protein Data Bank), the proximal contact between two areas.
The contact distances between C-alpha carbons were used to
HIV-1 Clade C gp120 Sequence Features during Disease Progression
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e95183
identify interactions between regions or differences between the
clades. A 10 A˚ cut-off distance between the C-alpha carbons was
considered as a measure for contact [27]. Contact maps were
generated with CMView v0.9.6, after loading the appropriate
molecular structure by specifying its PDB identification number.
The software allows to highlight relevant regions (e.g. C3 or C4 of
Env) or single residues of the loaded structure.
Statistical analysis
The Wilcoxon rank sum test was used to evaluate the statistical
significance of the difference between parameters analysed in the
study (if not explicitly stated otherwise).
Furthermore, to measure existing correlation between sequence
length and glycosylation status, the Spearman’s correlation test
was used. All analyses were conducted using the Stata 8.2 software.
Results
Phylogenetic analysis
We amplified and sequenced the V3-V5-coding regions of HIV
variants isolated from 72 HIV-infected individuals living in South
Africa and Swaziland, naı¨ve for ART during the years 2005 to
2007. A phylogenetic analysis based on the V3–V5 sequence
(Fig. 1) revealed that all patients were infected by HIV-1 subtype C
variants, as also previously described [9]. In the figure virus
sequences from patients have been highlighted with different
colors according to year of collection of sample: 2005 in blue, 2006
in red and 2007 in green. Since we wanted to study if and how
sequence molecular characteristics changed during the evolution
of the disease, we had to verify that the natural Env sequence
evolution through the three year period would not have influenced
the molecular analyses we performed. As it is evident in figure 1,
the different years are well intermixed in the figure, indicating that
the sampling year was not a main causal factor for the observed
differences in the sequence characteristics of the Env regions we
have considered for our studies. Furthermore, the phylogenetic
analysis in figure 1 shows an intermixing of all the sequences,
independently of the patient region of origin, indicating that a
possible, if any, difference in the ethnical background of the two
populations from Swaziland and South Africa does not constitute a
bias for the further analysis we performed.
Amino acid sequence length and PNGS distribution
Lengths of the amino acid sequences of the gp120 V3, C3 and
C4 regions from the HIV-1 infecting virus variant obtained from
each one of the 72 patients, as well as the predicted tropism of the
variant, are reported in Table 1. As shown in the Table, the
median length of amino acid sequences of the V3, C3 and C4
regions did not significantly vary with the disease stage. The V3
sequence length was equal to 35 amino acids in virus variants from
66 out of 72 samples, 34 amino acids in 5 variants, and 37 amino
acids in 1 variant. In the variants with a V3 sequence of either 34
or 37 amino acids, no correlation with disease stage was found. In
fact, of the five variants with a V3 sequence of 34 amino acids, 2
were from ES, 2 from CS and 1 from LS patients. The only
variant with a V3 sequence of 37 amino acids was obtained from
an LS patient. Regarding the predicted viral tropism, the three
sample groups presented a similar pattern with 20 out of 24
variants being R5 tropic and 4 being X4 tropic in the ES group;
19 R5 and 5 X4 tropic in the CS group and 18 R5 tropic and 6
X4 tropic in the LS group.
Amino acid sequence length of the C3 region ranged from 50 to
54 amino acids. No significant differences in sequence length
among the disease stages were observed (Table 1), although a
tendency to a broader length variability was detected in the ES
group where 15 variants had a C3 region of 52 amino acids, 4 of
53, 2 of 51, 2 of 50 and 1 of 54. In the CS and LS groups, the C3
region was more conserved with 21 variants bearing a C3 region
of 52 amino acids in both disease stages. The remaining 3 variants
in the CS group had a C3 region of 51 amino acids, whereas in the
LS group, 2 had a C3 region of 53 amino acids and 1 of 51 amino
acids. The C4 region length was of 41 amino acids in all 72
variants.
Table 2 reports the mean and median number of PNGSs for
each region and for each disease stage. Overall, both the median
and the mean number of PNGSs of each region did not show
statistically significant variations among the three disease stages. A
qualitative analysis of the distribution of PNGSs among the
different groups of patients is reported in figure 2. A number of
PNGSs, in particular, PNGS N301 (in V3), N332, N339 and N356
(in C3), and N442 and N448 (in C4) are conserved in variants
obtained from patients at all the disease stages with a frequency
higher than 70%, with the exception of PNGS 339 (numbering
according to HXB2 sequence) in the C3 region that is present in
virus variants obtained from patients at the LS stage where it is
represented with a frequency of about 60%. For this reason these
PNGSs have been named ‘‘fixed’’. Besides these, other PNGSs
were found with a lower frequency in all the regions. Most of these
PNGSs are represented with a frequency that is often ,20% and
are not constantly present in virus variants obtained from patients
at all disease stages. Therefore, they have been named ‘‘shifting’’
PNGSs, in agreement with previous reports [9,14,46,47]. The
majority of the shifting PNGSs are present in the C3 region in
variants obtained during the chronic stage of the disease, in
particular in the a2 helix (amino acids 335 to 352) and in the N-
terminal and in C-terminal portions of the C3 region. The PNGS
at position 362 was found with a frequency of 33.3% in the
variants from the CS group (encircled in the figure), whereas it is
present at much lower frequency in variants from the ES and LS
groups. A shifting PNGS between N442 and N448 in the C4 region
was detected only during the late stage of the disease (encircled in
the figure). Of note, we also found a low frequency of expression,
at all disease stages, of the glycosylated residue 295, which has
been described to be highly conserved in other HIV-1 subtypes
[47] that comprehends the last amino acid in the C2 region and
the first two in the V3 region. Since this PNGS is located between
the C2 and the V3 regions, it has not been reported in figure 2.
Analysis of positive selection
For each disease stage, we evaluated which amino acid residue
in the constant V3, C3 and C4 regions was under positive selection
pressure, by calculating the dN/dS ratio for each position. Table 3
lists the sites that have a mean dN/dS ratio .1 in variants from at
least one of the disease stages. The number of amino acid positions
under positive selection pressure is considerably higher in the C3
region at the chronic disease stage. In fact, in this region, ten,
twelve and three residues appear to be under positive selection in
the virus variants from ES, CS and LS groups, respectively. Nine
out of twelve residues under positive selection pressure in the
variants from CS group cluster in the N-terminal portion of the C3
domain, within the a2 helix (amino acids 335 to 352). Within the
V3 domain, only three sites are under positive selection pressure
(amino acids 300, 309 and 322) in variants from the CS group, two
in variants from the ES group (amino acids 300 and 322) and two
in variants from the LS group (amino acids 300 and 309). In the
C4 domain only one site is under positive selection pressure
(amino acid 429) in virus variants obtained at all disease stages. In
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this region, an additional amino acid at position 446 appears to be
under positive selection pressure only in the LS group.
We have then calculated the strength of the positive selection
pressure for each one of the identified residues. No statistically
significant difference between the set of weighted mean values (vi)
among the disease groups was found for both the V3 and C4
regions (data not shown). Conversely, for the C3 domain, a
significant difference (p = 0.00016) was found between the set of
weighted vi of the ES and CS groups (Fig. 3), with sequences from
variants of the ES group displaying residues with higher vi values
than the ones calculated for the CS group.
Molecular visualization of sites under positive selection
pressure
In order to characterize the positions of the residues under
positive selection in the gp120 protein, we mapped them on the
three-dimensional structure of the CD4-bound gp120 derived
from the HIV-1 JR-FL strain [45]. Figures 4, 5 and 6 show the
positions of the residues under positive selection in the C3, C4 and
V3 regions (spheres in purple), respectively. Sites in C3 from
variants obtained from the ES and CS groups are more numerous
than those found in the variants from the LS group (Fig. 4). These
sites are located in the a2 helix region (in blue), near the CD4-
binding site and close to residues critical for the binding to CCR5
(spheres in red). Residues within the C3 region that are critical for
the binding to CD4 (amino acids 366 and 368, not shown in the
figure, since hidden by the CD4 structure) are fully conserved in
virus variants obtained at all the three disease stages, as also
confirmed by the low Shannon Entropy values (data not shown).
In contrast, the number of sites under positive selection pressure in
the C4 region (Fig. 5) is small in the virus variants from all the
three disease groups. Again, these residues are placed near the
CD4-binding site or close to residues critical for CCR5 binding.
Finally, the few sites under positive selection in the V3 region are
all proximal to the highly conserved residues critical for CCR5
binding (Fig. 6).
Electric charge analysis and interaction between regions
In order to investigate whether the electric charges of C3 and
C4 regions of gp120 (that are the principal components of the
Figure 1. V3–V5 phylogenetic tree of HIV-1 strains from 72 HIV-1-infected patients in South Africa and Swaziland. Tree was rooted by
using the midpoint rooting method. Scale bar at the bottom indicates 7% nucleotide substitutions per site. The asterisk along a branch represents
the bootstrap value (significant statistical support) .70% and p,0.001 in the zero-branch-length test. Years of collection of samples are color-
highlighted: 2005 in blue, 2006 in red and 2007 in green. Country where sample collection was performed: SW = Swaziland; SA = South Africa.
doi:10.1371/journal.pone.0095183.g001
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CD4 binding site) can have an impact on the conformation of the
CD4 binding site, we calculated the electric charge of each one of
these regions and correlated it with the electric charges of all the
other variable regions. After computing all the total electric charge
(Qtot) correlations, we found statistically significant correlations
between C3 and V4 and between C3 and V5 regions. These
correlations are shown in figures 7 and 8. A negative correlation
was present in the C3-V4 interaction (increased Qtot in V4 region
and decreased Qtot in C3 region) at all stages of disease (Fig. 7).
This correlation was statistically significant in the LS group of
patients (panel c, p = 0.0090). The electric charge analysis of the
C3-V5 interaction showed a strong tendency to a positive
correlation (increased Qtot in both C3 and V5) in the virus
variants from LS group of patients (panel f, p = 0.0526). This
correlation was statistically significant when the interaction
between electric charges of a2 helix (in C3 region) and V5 was
considered (Fig. 8 panel f, p = 0.0192).
The correlations of the electric charges between C3 and V4, C3
and V5, a2 helix and V4, and a2 helix and V5 were then further
characterised by means of contact maps, which allowed us to
identify close spatial contacts between two regions. Figure 9 shows
the contact maps for C3-V4 and C3-V5 (Panel A), and a2 helix-
V4 and a2 helix-V5 (panel B) in the crystallographic structure of
the JR-FL gp120 bound to CD4 [45]. As shown in panel A (top),
C3 and V4, and C3 and V5 regions strongly interact (light blue
area). In particular, amino acids in C3 at positions 360, 362 and
364, which have been found under positive selection pressure in
the virus variants obtained during the chronic disease stage,
interact with N-terminal residues of V4 region (panel A, left). In
the interaction between C3 and V5 (panel A, right) a single residue
at position 360 of the C3 region, under positive selection pressure
in the variants from the chronic disease stage, was found to
interact with residues in the C-terminus of the V5 region.
In the panel B of figure 9, the interactions of a2 helix with V4
and V5 regions are reported. Residues 335, 336, 337, 343, 346,
347 and 350 in a2 helix, which have been found under positive
selection pressure in the chronic disease stage, interact with
residues in the C-terminal and N-terminal of V4 (left). Finally, a
single residue in the a2 helix, at position 349, interacts with one
residue in the C-terminal of the V5 region (right).
Discussion
The role of gp120 variable regions in HIV escape from immune
response has been previously investigated (9–17). However, the
role of constant regions of gp120 has not been thoroughly studied
to date. In the present work we focused on those gp120 constant
regions of HIV-1 clade C which are key in the binding to CD4
receptor and coreceptors and are involved in the processes of
HIV-1 cell entry and in host immune response. Amino acid
sequence lengths, PNGSs distribution, residues under positive
selection pressure and electric charges within the V3, C3 and C4
conserved domains of HIV-1 clade C variants obtained from
individuals at different stages of disease, were investigated. The
aim of the study was to evaluate if and how these sequence
characteristics in these constant regions were modulated during
the course of the disease.
The study was performed on only patients naı¨ve for ART to
avoid influence of antiretroviral therapy on variants selection. It
therefore provides a clearer picture of mechanisms of HIV
immune escaping in patients who are not treated with antiretro-
viral drugs, a condition that, unfortunately, is still common in
many poor developing countries where HIV is highly endemic.
We observed that the V3 sequence length is well conserved in all
the disease stages (35 amino acids, on average), as previously
reported [Los Alamos website. Available: http://www.hiv.
lanl.gov/content/sequence/HIV/COMPENDIUM/1999/7/
V3LoopEvolution.pdf. Accessed 2014 March 31, and 9, 23, 24],
since this length possibly ensures the optimal conformation for the
binding to CCR5 [48]. Virus tropism, predicted on the basis of the
V3 sequence, does not switch from R5 to X4 at the later disease
stage, as it has been instead described for the HIV-1 B subtype
[25,48–51], although a greater, but not significant, number of X4
strains have been observed at the late stage, when compared to
early and chronic stages.
The amino acid length of the C3 region ranged from 50 to 54
residues. In line with previous studies, we confirmed that the C3
domain in subtype C variants is relatively variable, in particular in
its a2 helix portion, although sequence length variability among
disease stages was not statistically significant. The a2 helix sub-
domain is more exposed to the solvent and to neutralizing
antibodies in clade C than in clade B virus and thus exhibits a
higher sequence entropy at the polar face [24]. Conversely, the C4
region was constant in its amino acid sequence length (41 aa) at all
the disease stages. This may be due to the fact that, although
Table 2. Number of PNGSs in gp120 V3, C3 and C4 regions of HIV-1 clade C variants from patients at different disease stages.
Number of PNGSs
Disease stage C3 C4 V3
ES Mean 2.75 1.71 1.00
Median 3.00 2.00 1.00
Range 2–4 0–2 0–2
CS Mean 2.96 1.71 0.96
Median 3.00 2.00 1.00
Range 1–4 1–2 0–1
LS Mean 2.67 1.83 0.96
Median 3.00 2.00 1.00
Range 2–4 1–2 0–1
ES = Early disease Stage; CS = Chronic disease Stage; LS = Late disease Stage.
doi:10.1371/journal.pone.0095183.t002
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Figure 2. Distribution of PNGS in V3, C3 and C4 regions of gp120 in HIV-1 clade C variants obtained during different disease
stages. Table at the bottom reports the frequency of presence of each PNGS. PNGS position in the alignment is according to the HXB2 amino acid
sequence numbering. Circles highlight a significant increase of shifting PNGS frequency ES = Early disease Stage CS = Chronic disease Stage LS =
Late disease Stage.
doi:10.1371/journal.pone.0095183.g002
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Figure 3. Strength of positive selection of sites in the C3 region during the early and chronic disease stages. The strength of positive
selection (v) for each amino acid site is reported in the y axis. Sites are reported in the x axis. Amino acids numbering is according to HXB2 sequence.
Grey and black bars show the strength of positive selection of each of the sites for the early infection stage (ES) and the chronic infection stage (CS),
respectively. Statistical significance of the difference between the two series: p = 0.00016.
doi:10.1371/journal.pone.0095183.g003
Table 3. Amino acid sites under positive selection in gp120 V3, C3 and C4 regions of HIV-1 clade C variants from patients at
different disease stages.
Mean dN/dS ratio
Region Position in HXB2 Position in JR-FL ES CS LS
V3 300 297 3.05660.699 3.05660.690 4.676+1.223
309 306 ,1 3.01960.718 4.676+1.226
322 317 3.05060.707 3.05060.696 ,1
C3 335 331 4.71160.995 3.50760.122 ,1
336 332 4.90260.598 3.50760.118 7.80861.550
337 333 4.86460.703 3.50560.138 ,1
343 339 4.90260.599 3.50760.120 ,1
344 340 4.90160.600 3.50760.118 ,1
346 342 4.90260.599 3.50760.118 ,1
347 343 ,1 3.50560.143 ,1
350 346 4.88560.648 3.50760.118 ,1
352 348 ,1 3.49460.220 ,1
360 355 4.90260.598 3.50460.145 ,1
362 357 4.90260.598 3.50760.118 7.80761.552
364 359 4.90260.598 3.50760.120 7.80861.550
C4 429 420 2.93560.911 5.32161.659 2.90560.591
446 437 ,1 ,1 2.89360.604
ES = Early disease Stage; CS = Chronic disease Stage; LS = Late disease Stage.
doi:10.1371/journal.pone.0095183.t003
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located together with the C3 region in the outer domain of gp120
protein, C4 is buried into a hydrophobic pocket and therefore is
less exposed to the selection pressure of the host immune response.
The number of conserved PNGSs in the V3, C3 and C4 regions
was constant at all the disease stages. All conserved PNGSs in
these regions are found in all M group viruses with a frequency .
70% [52]. A single fixed PNGS in V3, at position 301, involved in
coreceptor binding, was observed in the N-terminal portion [53].
No shifting PNGSs in V3 were observed at all disease stages, in
agreement with previous data indicating that in the V3 domain the
presence of shifting PNGSs is very rare, since appearance of new
PNGSs may interfere with co-receptor binding [10]. In addition,
we found a low frequency of expression of the glycosylated residue
295, located at the confluence of C2 and V3, within the target
epitope of the 2G12 monoclonal antibody. Absence of the 295
residue in the clade C variants explains the resistance of subtype C
strains to the neutralising effects of this monoclonal antibody [54].
In the C3 domain, shifting PNGS were mainly observed within the
a2 helix and the C-terminal portions, downstream of the
conserved PNGS N356. These amino acid positions are important
targets of neutralizing antibodies and the generation of new
PNGSs could provide a shield against the immune system
response. Interestingly, we have identified a PNGS at position
362 with a frequency of 33.3% in the CS group and with a much
lower frequency (8.3%) in the ES and LS groups. As observed by
Sterjovski et al., this residue, adjacent to the CD4-binding site, is
associated with an enhanced virus fusogenic capacity and entry
[55]. Since an increase in length of the amino acid sequence of V1
and V4 regions during the chronic stage of the disease may result
in a reduced affinity to the CD4 receptor [9,56], we can speculate
that the PNGS 362 in C3 may be selected during the chronic stage
to compensate the reduced affinity to CD4.
In the C4 region, two conserved PNGSs at positions 442 and
448 and a few shifting PNGSs between these two residues, have
been identified. The N442 residue was suggested to be involved in
glycan shielding [57,58], whereas the N448 residue is known to be
critical for the binding to CCR3 co-receptor, together with residue
N356 in C3 [59]. The N448 residue has also been reported to
protect the V3 loop from neutralizing antibodies and to promote
processing and/or presentation of T-helper epitopes for antiviral
T-cell response [60,61]. Since PNGSs in the C4 region are
positioned close to the pocket of the CD4-binding site, the shifting
PNGSs lying in that region may shield the virus from both
neutralizing antibodies and the T-helper mediated immune
response [14].
In an attempt to characterize other sites that could be involved
in virus escaping, we identified those sites in V3, C3 and C4 that
are under positive selection pressure at the different disease stages
and mapped them onto the three-dimensional structure of the
CD4-bound gp120 from the JR-FL HIV-1 virus [45]. Most of
these sites under positive selection pressure were found within the
C3 region and, in particular, in the a2 helix portion during early
and chronic disease stages. We also detected three sites in the V3
region under positive selection pressure during the chronic disease
stage, and two sites in both the early and late disease stages. The
presence of sites under positive selection pressure in the a2 helix
region, as well as in the V3 region, indicates a strong diversifying
selection of these regions, in a subtype-specific manner
[19,29,30,62].
Figure 5. Sites under positive selection pressure in C4 region at
different disease stages. HIV-1 gp120 protein model is from JR-FL
strain [45]. Sites under selection pressure are indicated as spheres in
purple. Labeling of each positively selected site is centered on the a-
carbon of the amino acid. CD4 receptor is in green. Residues involved in
CCR5 binding are indicated as spheres in red. The a2 helix region is
indicated in blue. Amino acid numbering is according to HXB2
sequence. ES = Early disease Stage CS = Chronic disease Stage LS
= Late disease Stage.
doi:10.1371/journal.pone.0095183.g005
Figure 4. Sites under positive selection pressure in C3 region at
different disease stages. HIV-1 gp120 protein model is from JR-FL
strain [45]. Sites under selection pressure are indicated as spheres in
purple. Labeling of each positively selected site is centered on the a-
carbon of the amino acid. CD4 receptor is in green. Residues involved in
CCR5 binding are indicated as spheres in red. The a2 helix region is
indicated in blue. Amino acid numbering is according to HXB2
sequence. ES = Early disease Stage CS = Chronic disease Stage LS
= Late disease Stage.
doi:10.1371/journal.pone.0095183.g004
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The presence of sites under positive selection pressure in C3
region of HIV-1 clade C subtype during the chronic disease stage
has been described in literature [63]. However, we also found a
strong reduction of sites under positive selection pressure in the C3
region during the late disease stage. This is the first time, to our
knowledge, that such an evidence is reported. Lastly, in the C4
region close to the CD4 binding site, two sites were found under
positive selection pressure during the late stage of the disease and
only one in the early and chronic disease stages. Of note, some of
the sites under positive selection pressure were also found close to
critical residues for binding to either CD4 or CCR5.
The strength of positive selection was found to be significantly
different among the disease stages only in the C3 region. In
particular, it was found to be significantly higher at the early stage
of the disease, when compared to the one at the chronic stage.
Taken together these data lead us to speculate that during the
early disease stage, when the immune response may be less
developed compared to the chronic stage, more degrees of
freedom for the three-dimensional structure of the viral particle
surface are allowed. Conversely, during the chronic disease stage,
the greater pressure generated by a more developed immune
response may lead to the selection of more non-synonymous
substitutions that are compatible with an increasingly constrained
three-dimensional conformation of the gp120 molecule in terms of
viral fitness, since fewer degrees of freedom are allowed. The
greater number of positive selected sites in the C3 region during
the chronic disease stage, in comparison to those observed during
the early stage, may be seen as a compensatory effect by which the
virus counteracts the lower strength of positive selection in the CS
stage with an increased number of positive selected sites in this
stage. This effect may, in turn, benefit a higher resistance of the
virus to the immune response, in particular to the action of
neutralising antibodies.
Since no significant differences in the number and the strength
of positive selection were observed in both V3 and C4 regions at
any disease stage, we propose that the C3 region could be a more
critical target for positive selection than C4 and V3, as already
suggested by Moore et al., using HIV-1 clade C chimera viruses
[6]. In this regard, data in literature indicate that the a2 helix in
HIV-1 subtype C is more exposed to the solvent than in HIV-1
subtype B and that the residues with dN/dS .1 are associated
with resistance to neutralization [24]. Electrical charge analysis
revealed a significant strong negative correlation between the total
electric charges of C3 and V4 in virus variants during the late
stage of disease coupled with a strong positive correlation between
the total electric charges of C3 (in particular the a2 helix) and V5
during the late stage of the disease. Contact maps analysis showed
that the N-terminus of the a2 helix and the C-terminus of the V4
region are in close proximity. This may be related to the charge
negative correlation between C3 and V4 (and a2 helix and V4),
seen in the variants at late disease stage, in agreement with
previously published data [24]. Similarly, C3, in particular the a2
helix, strongly interacts with V5, with a positive electric charge
interaction. Overall, data on electric charge and interaction
among regions suggest that during the course of the disease
changes in electric charge and strong physical interactions can
affect the conformation of the regions of gp120. These changes
may be instrumental in the virus escape mechanism. In fact, the
negative value of the charge cross-correlation between C3 and V4
in the late disease stage may indicate that an attractive force is
mediated by such changes, thus maintaining a more compact and
closed structure of the two regions. Contact maps indicate that C3
and V4 are in close proximity and show a spatial preference for
charged residues, suggesting that the negative correlation between
C3 and V4 can have a physical explanation in terms of
electrostatic interactions between these two regions. It could be
assumed that the negative C3-V4 correlation is the hallmark of an
electrostatic attraction between these two regions. This, in turn,
induces a conformational change in both regions towards a more
closed conformation that may protect the C3-V4 epitope from
neutralizing antibodies. The absence of a significant C3-V4
negative correlation during the chronic disease stage could be
compensated by the presence of the PNGS at position 362 in the
C-terminal region of C3, whose frequency is increased during
chronic disease stage. The PNGS at position 362 is near the CD4
binding site, and strongly interacts with the V4 region, as shown
by the contact maps. The presence of the glycan residue at
position 362 could, therefore, act as a shield against neutralizing
antibodies. In late disease, the electric charge-mediated attraction
between C3 and V4, which favors a more closed conformation,
could be counter-balanced by the repulsive forces between C3 (in
particular the a2 helix) and V5, shown here. These repulsive forces
could be responsible for a more open conformation of these two
regions. Since the orientation of V5 regulates the opening of the
CD4 binding pocket [55 and Cenci and D’Avenio, personal
communication], these data support the hypothesis that, when the
immune system becomes weaker with disease progression, a more
open conformation in these two regions may increase the fitness
for the binding to the CD4 cell receptor, as critical residues for
CD4 binding have been shown to be present in C3, in addition to
those present in C4 [30,31].
Figure 6. Sites under positive selection pressure in V3 region at
different disease stages. HIV-1 gp120 protein model is from JR-FL
strain [45]. Sites under selection pressure are indicated as spheres in
purple. Labeling of each positively selected site is centered on the a-
carbon of the amino acid. CD4 receptor is in green. Residues involved in
CCR5 binding are indicated as spheres in red. The a2 helix region is
indicated in blue. Amino acid residue 300 in V3 is partially hidden by
residue 441 of the C4 region, to which it is spatially close. Amino acid
numbering is according to HXB2 sequence. ES = Early disease Stage CS
= Chronic disease Stage LS = Late disease Stage.
doi:10.1371/journal.pone.0095183.g006
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It is also noteworthy that some sites under positive selection
pressure are found to be involved in the interactions between C3
and V4 (amino acids 360, 362 and 364 in C3) and between C3
and V5 (amino acids 360 and 362 in C3), hinting at a possible role
in conformational changes driven by the immune pressure.
Similarly, the contact map between the a2 helix and the V4
region indicates that the sites under positive selection pressure
within the a2 helix (residues 335, 336, 337, 343, 346, 347 and 350)
strongly interact with C terminal residues in V4 and with one
residue at V4 N-terminal. It is plausible that the a2 helix structure,
interacting with V4 through electric charge rearrangements, could
relocate the neutralizing epitope in the C3-V4 region, thereby
eluding the host’s neutralizing antibodies.
Conclusions
We have identified, for the first time and in a large sample of
virus variants, several distinguishing features in V3, C3 and C4
regions of HIV clade C gp120 protein. We have described the
variability of these features during the course of the disease and
speculated on possible implications in virus infectivity and
resistance to the host’s immune response. In particular, we
Figure 7. Electric charge correlations between C3-V4 and C3-V5 regions. Statistically significant p values are in bold. Rho = correlation
coefficient ES = Early disease Stage CS = Chronic disease Stage LS = Late disease Stage.
doi:10.1371/journal.pone.0095183.g007
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described the presence of sites in C3, C4 and V3 regions that are
under positive selection pressure and are proximal to residues
important for the binding to CD4 receptor or co-receptors, and
mapped them in critical areas of contact between these regions.
These sites may be instrumental to charge-associated conforma-
tional changes that may play a role in the evolution of HIV.
These findings may contribute significantly to the search for
new immunogens suitable for developing a sterilising vaccine
against HIV, as well as to the design of novel antiviral drugs.
Accession codes. Sequences included in this paper have been
deposited in GenBank under the accession numbers JN121046 to
JN121117.
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